Milford, CT, March 25, 2016 --(PR.com
)-- At the 2016 Miami Breast Cancer Conference (MBCC), Natalia Partain MD, Madhu Rao PhD, and Roshni Rao MD, FACS, from the Department of Surgery, Division of Surgical Oncology at the University of Texas Southwestern Medical Center presented their poster “Intra-operative Specimen Radiograph Utilizing 2D versus 3D Imaging and Correlation with Final Histopathology.”
The poster evaluated the differences in identifying 50 specimen radiographs that contained calcifications and had undergone both 2D and 3D imaging as a standard part of a surgical procedure. The results showed that tomosynthesis radiographs using Mozart® System with TomoSpec® Technology from Kubtec®, the world’s first and only 3D specimen radiography system, showed superior clarity of specimen margins when compared to the current technology.
This study, the first to correlate standard (2D) specimen radiographs versus tomosynthesis (3D) radiographs with final histopathology, effectively determined that intra-operative specimen radiography facilitates a reduction in surgical re-excisions in non-palpable cancers, thereby limiting scarring and trauma for breast cancer patients.
These results mirror those illustrated in a paper published by the Journal of Clinical Oncology, which states that “despite the availability of two-dimensional digital specimen mammography (2D), the re-excision rate for lumpectomy remains significant. Specimen tomosynthesis (3D) may provide a more detailed image than standard 2D with consecutive image slices of the lumpectomy specimens for immediate review.”
The MBCC poster concludes that “intra-operative specimen radiograph utilizing tomosynthesis allows for accurate assessment of margin status and facilitates reduced rates of re-excision for patients undergoing breast conserving therapy for cancer.” It also resolved that “tomosynthesis imaging allowed for better clarity of specimen edges – compared to 2D – and correlated well with final negative or positive margin status based on histopathology,” a decisive breakthrough in the treatment of breast cancer.
Kubtec, a registered trademark of KUB Technologies, Inc., develops and manufactures digital X-ray systems for clinical and non-clinical applications, including low-dose neonatal imaging, specimen radiography, scientific research, forensic analysis, non-destructive testing, irradiation and more. Kubtec is ISO 9001 and ISO 13485 certified and complies with U.S., Canadian, and European requirements for radiation safety. Systems and manufacturer-trained support is available worldwide.
For more information, please contact:
Mark A. Lugris
PR & Communications Manager
Tel: +1 203.364.8544 ext 106